Pemvidutide, Altimmune’s investigational once-weekly peptide, was developed primarily for serious liver diseases. Now it has produced a signal in a different condition: alcohol use disorder.
On November 9, 2026, researchers presented detailed results from the RECLAIM Phase 2 trial at The Liver Meeting in Denver, hosted by the American Association for the Study of Liver Diseases (AASLD).
In the 100-person randomized trial, participants receiving pemvidutide reduced their heavy drinking days by an adjusted average of 4.20 days per week over 24 weeks, compared with 2.75 days for participants receiving placebo.
The difference was statistically significant. The conference presentation also provided more detail about alcohol consumption, changes in an objective blood biomarker, body weight and a noninvasive marker of liver-fibrosis risk.
These findings build on Altimmune’s July RECLAIM topline results, which Grey Pepper previously covered.
The next milestone is regulatory. Altimmune says it has scheduled an End-of-Phase 2 meeting with the US Food and Drug Administration for December 2026 to discuss the design of a potential Phase 3 alcohol use disorder program.
The results are encouraging. But they remain evidence from a relatively small, company-sponsored Phase 2 trial, not proof that pemvidutide is ready to become an approved addiction treatment.
Why a Liver Drug Is Being Tested for Alcohol Use Disorder
Pemvidutide is a peptide designed to activate two hormone receptors: the glucagon-like peptide-1 receptor, usually abbreviated GLP-1, and the glucagon receptor.
Altimmune describes the molecule as a balanced 1:1 glucagon/GLP-1 dual receptor agonist.
GLP-1 receptor activation is already central to medicines used for type 2 diabetes and obesity. It affects appetite, satiety and glucose regulation. Researchers are also investigating its effects on brain pathways involved in motivation, craving and reward.
Glucagon receptor activation has a different metabolic profile, including direct actions in the liver. Altimmune is investigating whether combining the two mechanisms could be useful for metabolic dysfunction-associated steatohepatitis, known as MASH, and other serious liver diseases.
The company’s main late-stage program is PERFORMA, a global Phase 3 study of pemvidutide in MASH. That trial began in August 2026, with a 52-week data readout anticipated in 2029.
Alcohol use disorder offers another potential clinical application. Sustained heavy drinking increases the risk of alcohol-associated liver disease, while some patients also have obesity, metabolic dysfunction or excess liver fat.
Altimmune is testing the possibility that pemvidutide could reduce alcohol consumption while also addressing metabolic and liver-related risks.
That broader benefit remains a hypothesis. RECLAIM cannot determine whether glucagon receptor activation contributes independently to reduced drinking, because its design did not include a GLP-1-only comparator.
Nor can its alcohol-use results establish that pemvidutide prevents cirrhosis, reverses liver fibrosis or improves long-term liver outcomes.
The biological argument is plausible enough to test. Whether the dual mechanism provides benefits beyond existing GLP-1 treatments is a question that requires direct clinical evidence.
What the RECLAIM Phase 2 Trial Actually Tested
RECLAIM, registered as NCT06987513, was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial.
It enrolled 100 adults with moderate-to-severe alcohol use disorder and a body mass index above 25.
Fifty participants were assigned to pemvidutide and 50 to placebo. The active-treatment group received weekly injections, with treatment titrated toward a 2.4 mg dose, over a 24-week treatment period.
Both groups also received a standardized behavioral intervention delivered through monthly computer-based educational videos about alcohol misuse.
This detail matters because improvements in the placebo group occurred alongside structured participation in an alcohol-treatment study, not in the absence of any intervention.
According to the conference presentation, the average age was approximately 50 years in both groups, 52% of participants were women, and average body mass index was approximately 32.
Three-quarters of participants met criteria for severe alcohol use disorder. At baseline, participants averaged approximately 5.6 to 5.9 heavy drinking days per week, depending on treatment group.
The primary outcome was the change in heavy drinking days per week, assessed through a structured self-report method called Timeline Follow-back.
For the trial, a heavy drinking day meant consuming at least five drinks for men or at least four drinks for women.
The investigators also measured changes in World Health Organization drinking-risk categories, days without drinking, drinks consumed on drinking days and phosphatidylethanol, or PEth, a blood biomarker associated with recent alcohol exposure.
Ninety-one participants completed the study, while 79 completed their assigned treatment: 40 in the pemvidutide group and 39 in the placebo group.
That distinction is important. Remaining available for study assessments is not the same as completing all assigned treatment.
Pemvidutide Reduced Heavy Drinking Days More Than Placebo
The primary result remained the central finding at the November 9 presentation.
By week 24, heavy drinking days had fallen by an adjusted average of 4.20 days per week in the pemvidutide group, compared with 2.75 days per week in the placebo group.
The estimated treatment difference was 1.45 fewer heavy drinking days per week in favor of pemvidutide, with a 95% confidence interval of 0.58 to 2.32 fewer days and a reported p value of 0.0014.
Altimmune reported that treatment-group separation was observable by week four.
The placebo group’s improvement was substantial. That does not cancel the treatment effect, but it illustrates why the difference between randomized groups is more informative than the reduction within either group alone.
The trial also produced favorable results on two secondary outcomes that Altimmune describes as recognized by the FDA for registrational alcohol use disorder trials.
During the final four weeks, 42.2% of participants in the pemvidutide group experienced zero heavy drinking days, compared with 17.4% receiving placebo.
A reduction of at least two levels on the WHO drinking-risk scale occurred in 64.4% of the pemvidutide group and 34.8% of the placebo group.
Both differences were reported as statistically significant, with p values of 0.0066 and 0.0049, respectively.
Importantly, zero heavy drinking days is not the same as complete abstinence. A participant could avoid days above the heavy-drinking threshold and still consume alcohol on other days.
The study separately examined abstinent days. The adjusted increase from baseline in the percentage of days without alcohol consumption was 38.9 percentage points with pemvidutide versus 20.5 percentage points with placebo.
The difference was statistically significant.
The average number of drinks consumed on drinking days also fell in both groups. However, the between-group difference on that specific measure did not reach statistical significance in the AASLD presentation.
These outcomes suggest that the largest demonstrated effects involved the frequency and risk level of drinking, rather than a clearly established reduction in every measure of alcohol consumption.
The drug reduced heavy drinking more than placebo. It did not establish that participants stopped drinking altogether.
The Blood Test That Strengthens the Drinking Results
Self-reported drinking is useful in addiction research, but it has limitations. Participants may forget episodes, underestimate consumption or report behavior differently because they know they are being observed.
That makes the trial’s PEth findings particularly important.
Phosphatidylethanol is a group of compounds formed in blood in the presence of ethanol. Its concentration can provide objective supporting evidence of alcohol exposure over the preceding weeks.
At week 24, the adjusted mean change in serum PEth was a reduction of 153.4 ng/mL in the pemvidutide group, compared with an increase of 22.0 ng/mL in the placebo group.
The estimated between-group difference was approximately 175.4 ng/mL in favor of pemvidutide, with a p value below 0.0001.
The AASLD presentation showed the pemvidutide group’s PEth concentrations declining over the treatment period, while the placebo group’s adjusted changes remained closer to baseline.
That pattern supports the reported behavioral findings with a measurement that does not depend entirely on participants remembering and describing how much they drank.
It does not make PEth a perfect measure. Biomarker concentrations vary between individuals, and they cannot independently establish every occasion of drinking or the exact amount consumed.
Nevertheless, the combination of structured self-report and an objective alcohol biomarker makes the RECLAIM findings more persuasive than a study relying on questionnaires alone.
The Liver Finding Is Interesting, but Very Preliminary
Another result highlighted at AASLD involved the Fibrosis-4 index, or FIB-4.
FIB-4 is a noninvasive score calculated from age, liver enzyme measurements and platelet count. Clinicians use it to help assess the probability of advanced liver fibrosis and determine whether additional evaluation may be appropriate.
It is not a direct measurement of scar tissue, and changes in the score do not necessarily establish that liver fibrosis has reversed.
Among participants who had elevated FIB-4 scores at baseline, defined in the presentation as at least 1.3, Altimmune reported normalization below that threshold in 50% of pemvidutide recipients versus 17% of placebo recipients.
The underlying elevated-risk subgroup was small, with 25 participants at baseline: 10 assigned to pemvidutide and 15 to placebo.
These numbers make the observation worth investigating, but they are insufficient to establish prevention or reversal of clinically meaningful liver scarring.
Participants also lost body weight. Mean weight change was a reduction of 8.7% with pemvidutide and an increase of 0.4% with placebo, an estimated treatment difference of 9.1 percentage points.
Changes in weight, drinking behavior and liver enzymes can all influence liver-related risk markers. RECLAIM cannot determine which mechanism accounted for the observed FIB-4 difference.
Altimmune has a separate Phase 2 trial, RESTORE, examining pemvidutide in alcohol-associated liver disease. Enrollment was reported complete in August 2026, with data expected in the second half of 2027.
That study is a more direct test of liver-related questions than RECLAIM, which primarily evaluated drinking behavior.
The liver hypothesis should therefore remain separate from the demonstrated alcohol-consumption results.
The Tolerability Trade-Off: One in Ten Stopped Treatment Because of Drug-Related Events
The potential benefit comes with a safety and tolerability question.
As with other drugs acting on GLP-1 pathways, gastrointestinal adverse events were more common among people receiving pemvidutide.
Nausea was reported by 44% of pemvidutide recipients compared with 24% receiving placebo.
Vomiting occurred in 18% versus 6%, constipation in 26% versus 6%, and diarrhea in 20% versus 10%.
Altimmune described most adverse events as mild or moderate.
However, severe adverse events occurred in 12% of participants in the pemvidutide group, compared with 6% in the placebo group. Serious adverse events occurred in 4% and 2%, respectively.
One case of low blood sodium, or hyponatremia, in the active-treatment group was considered possibly related to the study drug by the investigator.
Overall treatment discontinuation was similar between groups: 20% with pemvidutide and 22% with placebo.
But the reasons for discontinuation matter.
Five participants receiving pemvidutide, equivalent to 10% of the treatment arm, discontinued because of adverse events attributed to the study drug. No placebo participants discontinued for that specific reason.
The events included two cases of vomiting, along with constipation, fatigue and worsening hemorrhoids.
A medication intended for alcohol use disorder would need to be tolerable over sustained treatment, including in patients who may have nutritional problems, liver disease or other complications of alcohol use.
The trial is too small to characterize rare adverse events reliably, and six months cannot establish long-term safety.
Similar overall dropout rates do not mean similar medication tolerability. The causes of discontinuation tell a more complicated story.
What RECLAIM Cannot Establish About GLP-1 Drugs and Alcohol
The most important limitation is scale. RECLAIM randomized 100 participants, and some secondary analyses involved fewer people.
The study lasted 24 weeks. It cannot show whether reductions in drinking persist for years or what happens when participants discontinue pemvidutide.
Its eligibility criteria also limit generalizability. The trial required a body mass index above 25, excluding leaner individuals with alcohol use disorder who may not benefit from losing substantial weight.
There was no active comparison with an established alcohol use disorder medicine.
In the United States, the FDA has approved naltrexone, acamprosate and disulfiram for alcohol use disorder. These treatments operate through different mechanisms and have different strengths and limitations.
RECLAIM therefore cannot establish whether pemvidutide is more effective, safer or better tolerated than existing therapies.
There is also the mechanistic question. Because pemvidutide activates both GLP-1 and glucagon receptors, its results cannot isolate the effects of either receptor.
And the evidence for GLP-1 drugs in alcohol use disorder is no longer limited to anecdotes.
In February 2025, a small randomized trial published in JAMA Psychiatry reported that once-weekly semaglutide reduced several measures of alcohol consumption and craving compared with placebo.
Additional randomized studies of semaglutide have since examined alcohol use disorder, including trials involving people with obesity.
These findings support continued investigation of the GLP-1 pathway, but results across different trials cannot be directly compared as though the same patients, doses and treatment durations were studied.
The available evidence does not demonstrate that adding glucagon receptor activity makes pemvidutide more effective against alcohol use disorder than a GLP-1-only medicine.
Finally, although the detailed results were presented at a scientific meeting, conference presentation is not equivalent to a complete peer-reviewed publication. The full statistical methods, supplementary analyses and final manuscript remain important for independent assessment.
Why the December 2026 FDA Meeting Matters
Altimmune’s next significant step is a scheduled End-of-Phase 2 meeting with the FDA in December 2026.
Such meetings allow developers and regulators to discuss the evidence available so far and the design of future clinical trials that may support a marketing application.
For pemvidutide, the questions include which clinical endpoints should be prioritized, how long treatment should last, which patients should be enrolled, what safety information is required and how many participants a pivotal program would need.
Altimmune has emphasized that both a two-level reduction in WHO drinking-risk categories and zero heavy drinking days are recognized by the FDA as potential registrational endpoints for alcohol use disorder.
That does not mean the agency has approved pemvidutide, endorsed the RECLAIM results as sufficient for approval or agreed to a specific Phase 3 design.
The FDA could request changes to the proposed trial population, endpoint definitions, follow-up duration or safety monitoring.
A larger study may also produce different results from RECLAIM, even if its design is scientifically sound.
The December discussion matters commercially as well. A pivotal alcohol use disorder program would require substantial funding while Altimmune is already pursuing late-stage development in MASH.
At the end of June 2026, the company reported approximately $519 million in cash, cash equivalents and investments.
Its third-quarter 2026 financial results are scheduled for November 12. Those results should provide an updated view of the resources available for multiple clinical programs.
Altimmune also holds FDA Fast Track designation for pemvidutide in alcohol use disorder and MASH, along with Breakthrough Therapy designation for MASH.
These designations may facilitate aspects of regulatory development, but they are not marketing approvals and do not substitute for successful clinical trials.
RECLAIM establishes a promising Phase 2 signal. The FDA meeting will help determine what evidence must come next.
The Bottom Line: Pemvidutide Has a Signal, Not an Approval
The November 9 AASLD presentation strengthened the case that pemvidutide deserves further investigation in alcohol use disorder.
The primary endpoint was met. Important secondary drinking-risk measures favored pemvidutide. And the decline in the objective PEth biomarker supports the self-reported reductions in alcohol consumption.
Those are meaningful findings from a randomized human study.
But RECLAIM remains a small Phase 2 trial with limited follow-up, substantial gastrointestinal adverse events and no direct comparison with existing treatments or a GLP-1-only medicine.
The reported FIB-4 changes add an interesting liver-related observation, not proof that the drug prevents or reverses alcohol-associated liver damage.
For Altimmune, the December FDA meeting will help define whether the program can move toward a pivotal trial and what that trial must demonstrate.
For the broader peptide field, the study adds to a growing body of randomized evidence that drugs developed for metabolic disease may also affect patterns of alcohol consumption.
The most important questions now concern durability, safety, patient selection and whether the dual receptor mechanism adds anything that existing GLP-1 medicines cannot.
Pemvidutide reduced heavy drinking in this trial. Whether it can become a safe, effective and practical treatment for alcohol use disorder remains a question for larger studies.
Sources and Further Reading
- Altimmune. Positive Late-Breaking Pemvidutide Data Presented at AASLD The Liver Meeting 2026. November 9, 2026.
- Kranzler HR et al. Efficacy and Safety of Pemvidutide in Adults with Alcohol Use Disorder: RECLAIM Phase 2 Trial. AASLD Oral Presentation, November 9, 2026.
- Kranzler HR et al. RECLAIM Phase 2 Clinical Trial Results. AASLD Scientific Poster, November 9, 2026.
- Altimmune. Positive Topline Results from the RECLAIM Phase 2 Trial in Alcohol Use Disorder. July 28, 2026.
- ClinicalTrials.gov. RECLAIM Phase 2 Study of Pemvidutide in Alcohol Use Disorder, NCT06987513.
- Altimmune. Second Quarter 2026 Financial Results and Business Update. August 12, 2026.
- BioSpace. Altimmune Gears Up for FDA Meeting on Pivotal Phase 3 Trial in Alcohol Use Disorder. November 10, 2026.
- Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2025.
- Randomized Placebo-Controlled Trial of Semaglutide in Alcohol Use Disorder with Comorbid Obesity. PubMed, 2026.
- National Institute on Alcohol Abuse and Alcoholism. Treatment for Alcohol Problems: Finding and Getting Help. Overview of Approved Alcohol Use Disorder Medications.
